Neurosurgery: Clinical Studies Open For Enrollment
Eligibility
- 18 years to 90 years of age
- Pre-morbid Modified Rankin Score less than or equal to 3
- Confirmed diagnosis of subacute or chronic subdural hematoma
- Completed informed consent
- Meets criteria for Surgery or Observation Cohort
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04402632
Principal Investigator
Justin Santarelli, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Middle Meningeal Artery EMbolization for the Treatment of SuBduRal HemAtomas with TRUFILL® n-BCA (MEMBRANE)
Eligibility
- 18 years to 90 years of age
- Pre-randomization mRS less than or equal to 3
- Confirmed diagnosis of chronic subdural hematoma
- Completed informed consent
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04816591
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
A Prospective, Multi-Center, Single Arm Study to Obtain "Real World" Clinical Data and Characterize the Acute and Long-Term Performance of the Micrusframe and Galaxy Coils Including the Pulserider Aneurysm Neck Reconstruction Device for the Endovascular Treatment of Intracranial Aneurysms (STERLING)
Eligibility
- Patient is between 21 and 80 years of age
- Patient has an intracranial saccular aneurysm, ruptured or unruptured, suitable for embolization with coils
- Patient is able and willing to comply with protocol and follow-up requirements
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT03642639
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
A Prospective Non-Invasive Study of Cerebral Blood Flow Velocity Morphology for Quantification of Intracranial Pressure (ICP)
Eligibility
- Subject is between 18-80 years of age
- Subject with diagnosis of Traumatic Brain Injury (TBI) or Stroke (i.e. Hemorrhagic Stroke)
- Subject with invasive ICP monitor (ventriculostomy, or other)
- Subject or Legally Authorized Representative has the ability to provide informed consent and comply with the protocol.
Enrollment Status: Actively enrolling
Study Information
Grant ID: W81XWH1720058
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
A Multicenter Observational Study of GammaTileTM Surgically Targeted Radiation Therapy in Intracranial Brain Neoplasms (STaRT): Solid Tumor
Eligibility
Patients eligible for this study have been diagnosed with a malignant brain tumor and, with their doctor, decided to use GammaTiles, a type of radiation treatment, to help treat their brain tumor after surgery.
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04427384
Principal Investigator
Simon Hanft, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase 2b Study to Assess the Safety and Efficacy of IGV-001, an Autologous Cell Immunotherapy with Antisense Oligonucleotide (IMV-001) Targeting IGF-1R, in Newly Diagnosed Patients with Glioblastoma (Imvax 14379)
Eligibility
This study is being conducted for adult participants (≥18 – 70 years old) that have a brain tumor called a glioblastoma (GBM). The purpose of the study is to see whether a combination of the investigational drug (IGV-001) plus standard of care (SOC) or placebo plus SOC is more effective in slowing GBM tumor regrowth and to see if IGV-001 is safe.
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04485949
Principal Investigator
Simon Hanft, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Evaluation of Immunological Responses against Glioblastoma (GBM) Solid Tumors (NIP-FTP-03)
Eligibility
Patients eligible for this study are scheduled to undergo brain surgery (craniotomy) to treat suspected or diagnosed glioblastoma (GBM), a type of brain cancer. Participation in this study includes donation of tumor tissue and a blood sample, and some information from medical records.
Enrollment Status: Actively enrolling
Principal Investigator
Simon Hanft, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
US IDE Study of the Contour NEurovasCular System™ for IntraCranial Aneurysm Repair (NECC Trial)
Eligibility
The purpose of this research study is to show whether an investigational device, called the Contour Neurovascular System™, is safe and effective to control brain aneurysms in adult patients (18-75 years old). The Contour Neurovascular System™ is a brain implant intended to stop the growth of brain aneurysms and form a barrier between the aneurysm and the blood flow.
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04852783
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Anticoagulation in Intracerebral Hemorrhage (ICH) Survivors for Stroke Prevention and Recovery (ASPIRE)
Eligibility
Patients eligible for this study are at least 18 years old and will have recently been diagnosed with a brain hemorrhage. Eligible patients will have also been diagnosed with an irregular heart rate which is a condition known as atrial fibrillation. This study is being done because survivors of intracerebral hemorrhage (ICH) who have atrial fibrillation (AF) are at high risk for subsequent ischemic stroke. An “ischemic” stroke is an injury to the brain caused by a blocked blood vessel supplying the brain. Atrial fibrillation is a common cause of ischemic stroke. In people with atrial fibrillation, blood clots can form in the heart. These clots can break free, travel to the brain, block a blood vessel, and cause a stroke. Blood thinners are the best way to decrease the risk of ischemic stroke in patients with atrial fibrillation. Apixaban (also known as Eliquis®) and aspirin are two types of blood thinner medications. The purpose of this research study is to compare the effects (good and bad) of apixaban with the effects (good and bad) of aspirin in patients with atrial fibrillation and a recent brain hemorrhage to see which is better at preventing future strokes and death. Apixaban is approved by the U.S. Food and Drug Administration (FDA) for stroke prevention in patients with atrial fibrillation. The FDA does not address the use of apixaban in patients with Atrial Fibrillation who have suffered an ICH because apixaban has not been studied in these patients.
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT03907046
Principal Investigator
Stephan A. Mayer, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Eligibility
- Male or female at least18 years of age
- Participants who have an acute onset of neurological deficit attributed to non-cardioembolic focal brain ischemia; Non-cardioembolic ischemic stroke with NIHSS ≤ 15 at randomization and/or High-risk TIA with complete resolution of symptoms within < 24 hours and an ABCD2 score ≥ 6 with negative neuroimaging (CT or MRI) for acute ischemia.
- Cerebrovascular atherosclerosis defined as vascular imaging (CTA, MRA, ultrasound, DSA) showing atherosclerotic plaque involving intracranial or extracranial cerebral arteries or the aortic arch.
- Plan for secondary prevention of stroke/TIA with single or dual antiplatelet therapy including ASA, clopidogrel, ticagrelor, prasugrel, cilostazol and dipyridamole and in line with local guidelines.
- Exclusion: for matched healthy controls; Recent ischemic stroke within seven days before index stroke event, Dysphagia with inability to safely swallow study medication at time of randomization and History of atrial fibrillation / flutter, left ventricular thrombus, mechanical valve or other cardioembolic source of stroke requiring anticoagulation.
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT05686070
Principal Investigator
Stephan A. Mayer, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Eligibility
- Male or female at least 18 years of age
- One to four newly diagnosed brain metastases, identified on the screening MRI, from an extracranial primary tumor.
- One lesion, designated the index lesion, is planned for surgical resection and is to be between 2.5 cm and 5.0 cm on the screening MRI. Index lesions > 2.0 cm but <2.5 cm are also eligible if surgery is deemed clinically necessary and appropriate for an attempted gross total resection by the neurosurgeon.
- Non-index lesions must measure < 4.0 cm in maximal extent on the screening MRI brain scan. The unresected lesions will be treated with SRT as outlined in the treatment section of the concept.
- All metastases must be located > 5 mm from the optic chiasm and outside the brainstem. Dural based metastasis are eligible.
- KPS score of ≥70.
- Adequate renal and hepatic function to undergo surgery, in investigators opinion.
- Ability to complete an MRI of the head with contrast
- Exclusion: for matched healthy controls; KPS<70, Past radiation or surgical therapy to the index lesion or the newly diagnosed, Primary germ cell tumor, small cell carcinoma, or lymphoma.
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT04365374
Principal Investigator
Simon Hanft, MD
Contact for Study Screening
Sooyun.Tavolacci@wmchealth.org
Eligibility
- Male or female at least 18 years of age
- Acute ischemic stroke clinically eligible for immediate EVT
- Time from onset (or last-seen-well) to randomization <12 hours
- Disabling stroke defined as follows:
- Baseline National Institutes of Health Stroke Scale (NIHSS) score >5 at the time of randomization
- NIHSS 3-5 with disabling deficit (e.g. hemianopia, aphasia, loss of hand function) as determined by the attending physician in context of the patient's life situation
- Confirmed symptomatic and endovascularly treatable MeVO based on neurovascular non-invasive imaging (mCTA or MRA), at one or more of the following locations: M2 or M3 segment, A2 or A3 segment, P2 or P3 segment1.
- Exclusion criteria:
- ASPECTS ≤ 5
- Well demarcated hypodensity in the majority of the brain parenchyma supplied by the occluded vessel or absence of collaterals in the affected territory on the delayed phases of the mCTA OR 9b. NCCT + (m)CTA + CTP**
- Lack of core: penumbra mismatch (if the CTP is uninterpretable, e.g., due to motion artifacts, apply exclusion criteria from 9a. If single-phase CTA is performed, score collaterals accordingly. If NCCT + mCTA + CTP are all performed, the core: penumbra mismatch criteria are sufficient for exclusion) OR 9c. MRI
- Diffusion restriction in the majority of the brain parenchyma supplied by the occluded vessel
Enrollment Status: Actively enrolling
Study Information
ClinicalTrials.gov | NCT05151172
Principal Investigator
Chirag Gandhi, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org
Eligibility
- Male or female, between 18 and 89 years of age at the time of procedure
- Angiographic confirmation of LVO of the internal carotid artery (ICA), middle cerebral artery (MCA; M1 or M2), basilar artery, or vertebral artery
- Used CEREGLIDE™ 71 Intermediate Catheter as the first attempted device for mechanical thrombectomy for the intracranial occlusion in the subject (direct aspiration or co-aspiration) or if a subject had another mechanical thrombectomy device without achieving mTICI 2b or better and continues to have angiographic confirmation of a Large Vessel Occlusion (LVO) in the same vessel.
- Deployment of CEREGLIDE™ 71 Intermediate Catheter
- Exclusion criteria:
- Enrollment in another AIS study with related endpoints
Enrollment Status: Actively enrolling
Principal Investigator
Fawaz Al-Mufti, MD
Contact for Study Screening
Cristina.Falo@wmchealth.org